Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-11-19

Clinical Trial Update: Long-term Study of DSP-5423P in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 long-term study of DSP-5423P in schizophrenia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DSP-5423P

Snippet

Sponsor: Sumitomo Pharma Co., Ltd. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2020-11-19